The Canadian Press on MSN18h
TPH saw ‘many deviations’ at gynecologist’s clinic with potential HIV, hepatitis exposure
Toronto Public Health says it observed “many deviations from best practices” during an inspection at the gynecologist's ...
MIT Technology Review1d
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Health and Me on MSN1d
Yearly Jab For HIV Protection Is Now Almost Here
A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
STAT3d
HIV self-testing is easy, effective — and underutilized
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
STAT4d
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
The Canadian Press on MSN4d
Potential HIV, hepatitis exposure at Toronto gynecology clinic has patients worried
The letter said patients who received endometrial biopsies, IUD insertions or had cervical growths removed at the clinic ...
Becker's Hospital Review1d
Baystate hospital alerts patients of possible infection exposure
Baystate Wing Hospital in Palmer, Mass., has contacted an unknown number of patients who may have been exposed to hepatitis or HIV due to a potential sterilization issue during surgeries performed ...
The Lancet4d
The potential for annual long-acting HIV pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
Applied Clinical Trials Online2d
Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
The Scientist3d
Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...